Makena, which is manufactured by KV Pharmaceutical of St. Louis, won FDA approval in February. The drug must be injected every week for approximately 20 weeks, putting the total cost at $30,000 per at-risk pregnancy. According to the report, the same compound has been available for years for only $10 or $20 per shot.
KV Pharmaceutical says the price is reasonable because the company is spending $200 million to develop the drug and conduct follow-up studies demanded by the FDA. Critics have responded saying the main study used to demonstrate Makena’s effectiveness was a $5 million project funded by taxpayers and provided through the National Institutes of Health.
Read the Nashua Telegraph report on Makena.
Read more on supplies:
–Virginia Hospitals Adapt to Drug Shortages
–Drug Shortages Cost Providers $200M Annually, Endanger Patient Safety
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
